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Comprehensive Profiling of Metaplastic Breast Carcinoma Reveals Frequent Over-Expression of PD-L1 
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Abstract (updated) 
Background: Metaplastic breast carcinoma (MBC) is a rare subtype of breast 
carcinoma less responsive to conventional chemotherapy relative to usual 
breast carcinomas such as ductal and lobular subtype. In molecular terms, 
MBC usually clusters with triple negative breast cancers (TNBC), but MBCs 
portray a worse prognosis in comparison with TNBC. Published studies 
investigating MBCs for specific biomarkers of therapy response are rare and 
limited by the methodological approaches. 
Methods: 297 samples [MBC (n=75), triple-negative breast cancer of no-
special-type (TNBC-NOS, n=106), HER2-positive breast cancers (n=32) and 
luminal breast cancers (n=84)] were profiled using direct sequencing analysis 
[Illumina MiSeq Next Generation Sequencing (NGS)]. Immunohistochemistry 
for PD-L1 (SP142, Spring Bioscience) and PD-1 (NAT105, Ventana) was 
performed using automated procedures.   
Results: 89% MBCs exhibited triple-negative immunophenotype (ER-/PR-
/HER2-). The most common mutations in MBCs included TP53 (67%) and 
PIK3CA mutations (23%). Other mutations were rare including HRAS mutations 
(7%), STK11 (5%), FBXW7, PTEN, c-MET and JAK3 (4%, respectively). PD-L1 
expression on cancer cells was detected in significantly higher proportion of 
MBCs (46%) than in other molecular subtypes (6% in luminal and HER2+ breast 
cancers, respectively and 9% in TNBC-NOS, p<0.001). PD-1 positive tumors 
infiltrating lymphocytes (TILs) varied greatly in MBCs (0 to >50/mm2). 
Conclusion: Comprehensive profiling of a large cohort of this rare carcinoma 
highlighted predominance of TP53 mutations, wild type EGFR gene expression, 
a distinct increase in proportion of PD-L1 expression in carcinoma cells, and 
PD-1 expression in TILs. The latter properties can be exploited in clinical trials 
utilizing immune check point inhibitors.  
Background 
Metaplastic breast carcinoma (MBC) encompasses a group 
of mammary neoplasms characterized by differentiation of 
the neoplastic epithelium into squamous or mesenchymal 
cells (1). It is  less responsive to conventional chemotherapy 
compared to the usual ductal and lobular breast 
carcinomas (2). In molecular terms, MBC usually clusters 
with triple negative (ER-/PR-/ Her2-) breast cancer (TNBC), 
but MBCs portray a worse prognosis in comparison with 
TNBC. Published studies investigating MBCs for specific 
biomarkers of therapy response are rare and limited by the 
methodological approaches (3, 4). 
 
Methods 
The study included 297 samples [MBC (n=75), triple-negative 
breast cancer of no-special-type (TNBC-NOS, n=106), HER2-
positive breast cancers (n=32) and luminal (ER+/Her2-) breast 
cancers (n=84)]. The samples were profiled using direct 
sequencing analysis [Illumina MiSeq Next Generation 
Sequencing (NGS)] using formalin-fixed paraffin embedded tissue 
blocks. Immunohistochemistry for PD-L1 (SP142, Spring 
Bioscience) and PD-1 (EH12.1, Pharmingen) was performed using 
automated procedures.  
 
Figures 1A-D, 2A-D. Despite various morphologic appearances (A, C) of 
metaplastic carcinomas, strong PD-L1 overexpression (B, D) was observed in 
nearly 50% of the cases. 
Conclusions 
Metaplastic carcinomas are characterized by 
increased PD-L1 expression in carcinoma cells, and 
PD-1 expression in TILs, which can be exploited in 
clinical trials utilizing immune check point 
inhibitors in this hard-to-treat subtype of breast 
cancer.  
Comprehensive mutational profiling of MBC   
highlighted predominance of TP53 and PIK3CA 
mutations  and a wild type EGFR gene expression. 
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PD-1 and PD-L1 expression in metaplastic carcinoma 
Figure 1 Figure 2 
Table 1. PD-L1 expression was significantly higher in metaplastic carcinomas in 
comparison with other breast cancer subtypes (46% vs. 6-9%, p<0.001).  
 Overall PD-L1 positivity among 75 metaplastic  
breast carcinomas was 46%; highest of all types.  
Results (updated)  
Mean age of patients: 57 years (range, 35-93 years). 
Histology: MBCs exhibited various morphologic features 
including squamous, myoepithelial, spindle, and rhabdoid 
morphology with heterologous elements: bone (n=3) and 
cartilage (n=22 cases).  
ER, PR and HER2 status were available for 71 patients; 63 cases 
(89%) of MBCs exhibited triple-negative phenotype; the 
remaining 8 cases (11%) were ER/or PR positive (7 cases) and 
HER2 positive (1 case). 
Table 2. The stratification of MBCs into 4 types (5) on the basis of 
PD-L1 and TILs status; The proposed stratification is a framework 
to tailored (tailor) immunotherapy against tumor 
microenvironment (TME); 
PD-1 positive tumors infiltrating lymphocytes (TILs) varied greatly 
in MBCs (0 to 400/mm2, mean: 67.3). No significant association 
was found between the number of TILs and PD-L1 status 
(p=0.209). 
Mutational profiling of metaplastic carcinoma 
72 MBCs were tested by NGS of which 57 cases had 
interpretable results. Mutations were detected in 16 out of 45 
tested genes affecting 48 out 57 metaplastic carcinomas (84%). 
TP53 mutation was the most frequent mutation (32/57, 56%). 
In 20 cases, TP53 was the sole mutation detected in the tumor 
tissue while in the remaining 12 cases other mutations co-
occurred. PIK3CA mutation was the second most common 
mutation (13/72, 23%) while HRAS mutations was detected in 4 
cases (7%), STK11 in 3 cases (5%), FBXW7, PTEN, c-MET and 
JAK3 in two cases, respectively (4%). Single cases harbored 
mutations of AKT1, APC, BRAF, RET, c-KIT, MLH1, RET, and 
SMAD4 genes. None of the cases harbored EGFR mutation. 
 
